MMP-2-targeted GLP-1 nanotherapy boosts endothelial repair and prevents intracranial aneurysm recurrence in rats.
Background
Intracranial aneurysm (IA) is a critical cerebrovascular condition, often leading to subarachnoid hemorrhage with high mortality. Current treatments, like endovascular coiling, effectively prevent immediate rupture but face significant challenges with long-term recurrence due to incomplete or dysfunctional re-endothelialization. There's a pressing need for strategies that actively promote vascular repair. Glucagon-like peptide-1 (GLP-1) and its receptor agonists are known for their cardiovascular benefits, including enhancing endothelial nitric oxide production and promoting endothelial progenitor cell (EPC) mobilization, making them promising candidates for improving vascular healing.
Study Design
Researchers developed a novel GLP-1@tMSN (targeted mesoporous silica nanoparticle) system, functionalized with GLP-1 and designed to target matrix metalloproteinase-2 (MMP-2). This nanodelivery platform aimed to localize GLP-1's effects. The efficacy of GLP-1@tMSN was evaluated in a rat model of coiled intracranial aneurysm. The study assessed EPC recruitment and re-endothelialization through histological analysis and immunofluorescence. Mechanistic investigations focused on the Wnt/β-catenin signaling pathway, and preliminary safety was also evaluated.
Results
In the rat model of coiled intracranial aneurysm, GLP-1@tMSN significantly enhanced the recruitment of endothelial progenitor cells (EPCs) and robustly promoted re-endothelialization. Histological analysis after 28 days revealed the formation of mature endothelial-like tissue in the treatment group, a stark contrast to the fibrous tissue observed in the control group. Immunofluorescence analysis specifically confirmed the preferential accumulation of CD34+VEGFR2+ EPCs at the lesion site, highlighting the targeted nature of the nanotherapy.
Concurrent activation of the
Wnt/β-cateninpathway was observed, strongly implicating its pivotal role in driving the observed vascular repair mechanisms. Preliminary safety evaluations further indicated a favorable biocompatibility profile for the developed nanotherapeutic system, suggesting low systemic toxicity and good local tolerability.
Key Findings
- GLP-1@tMSN significantly enhanced endothelial progenitor cell (EPC) recruitment in a rat intracranial aneurysm model.
- Mature endothelial-like tissue formed after 28 days with GLP-1@tMSN, unlike fibrous tissue in controls.
- Preferential accumulation of
CD34+VEGFR2+EPCs was observed at the aneurysm lesion site. - The
Wnt/β-cateninpathway was activated, indicating its crucial role in driving vascular repair. - The GLP-1 nanotherapeutic system demonstrated a favorable preliminary biocompatibility profile.
Why It Matters
This targeted GLP-1 nanotherapy represents a significant step towards improving outcomes for patients with intracranial aneurysms post-embolization. By specifically enhancing localized GLP-1 efficacy, this approach could accelerate re-endothelialization, directly addressing a key factor in aneurysm recurrence. The ability to promote mature endothelial tissue formation offers a novel strategy to stabilize treated aneurysms and potentially reduce long-term recurrence rates. While currently preclinical, this work lays the groundwork for future clinical translation, potentially leading to a new adjunctive therapy that complements existing mechanical interventions and improves patient prognosis.
intracranial-aneurysm
glp-1
nanotherapy
re-endothelialization
endothelial-progenitor-cells
wnt-beta-catenin